Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer
- 1 May 2011
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 21, S9-S11
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late RelapseJournal of Clinical Oncology, 2010
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJournal of Clinical Oncology, 2006
- Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian CancerOncology, 2006
- Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistanceInternational Journal of Gynecological Cancer, 2005
- Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistanceInternational Journal of Gynecological Cancer, 2005
- Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecologic Oncology, 2004
- The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro modelGynecologic Oncology, 2004
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003
- Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.Journal of Clinical Oncology, 1995